What Harvard Stem Cell Institute does

Harvard Stem Cell Institute (HSCI) is a University-wide interfaculty initiative within Harvard University, founded in 2004 by Doug Melton and David Scadden to advance stem cell and regenerative biology toward clinical application. It operates as a network of more than 350 research faculty and their labs distributed across Harvard's schools, centers, eight affiliated teaching hospitals, and partner companies in Cambridge and Boston, organized around nine disease programs (Blood, Cancer, Cardiovascular, Diabetes, Kidney, Musculoskeletal, Nervous System Diseases, Skin, and Aging & Fibrosis). The institute also provides shared core facilities including the iPS Core Facility, the Center for Stem Cell Bioinformatics, and the Center for Human Cell Therapy, plus training programs such as the HSCI Internship Program and MD/PhD Fellowships.

HSCI's core technology stack spans induced pluripotent stem (iPS) cell derivation, CRISPR-Cas9 and related gene editing, organoid culture systems, and bioengineered tissue platforms for disease modeling and therapeutic development. The institute seeds high-risk/high-reward research through Capstone Grants (~$250K/investigator/year for 3-5 years), Seed Grants ($50K/year for up to two years), and the Barry Family HSCI Innovation Award ($250K annually), with a third of its grants reportedly attracting follow-on funding at approximately three times the original investment.

HSCI is a non-profit academic research institute and does not sell commercial products. Its revenue model rests on philanthropic giving, foundation grants, NIH funding, fee-for-service work at the iPS Core Facility, and technology licensing and startup formation. Discoveries are translated through licensing deals (e.g., Vertex Pharmaceuticals licensing the Melton Lab beta cell technology for VX-880), industry collaborations (Bristol-Myers Squibb, Boehringer Ingelheim, Frequency Therapeutics), and a startup ecosystem of 50+ faculty-founded companies including Moderna Therapeutics, CRISPR Therapeutics, Semma Therapeutics (acquired by Vertex in 2019), Fate Therapeutics, Sana Biotechnology, Garuda Therapeutics, and Elevian. Leadership transitioned in spring 2026 with Lee Rubin appointed as co-director alongside David Scadden, succeeding co-founder Doug Melton.

Name

Harvard Stem Cell Institute

Legal name

Harvard Stem Cell Institute

Website

https://hsci.harvard.edu

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Harvard Stem Cell Institute is a Harvard University research initiative advancing stem cell and regenerative biology across 350+ faculty, nine disease programs, and shared core facilities, funding early-stage research and translating discoveries into clinical applications through licensing and a startup ecosystem.

Ownership category

akta.pro rank

Product category

Biomedical Research - Stem Cell and Regenerative Medicine

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Stem Cell–Based Regenerative Therapies (HLAAAGAA)

akta.pro secondary industries

Biomedical Sciences & Medical Research Institutes (University-Based) (EDAHAGAI), STEM-Focused Research Universities (Engineering & Applied Sciences) (EDAHABAB)

Keywords

• Stem cell research
• Regenerative medicine
• Translational research
• Biomedical research funding
• Research training programs

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. Philanthropic Gifts and Grants: HSCI depends on sustained support from individuals, foundations, and company leaders. Philanthropic gifts are leveraged to attract NIH and other larger funding sources. A third of grants attract further funding at approximately 3x HSCI's original investment.
2. Technology Licensing and Startup Revenue: Discoveries from collaborative projects are often licensed, enabling venture capitalists and industry to invest. Startup companies develop foundational discoveries into new therapeutic products and platforms, creating potential licensing and royalty streams.
3. Fee-for-Service Core Facilities: The iPS Core Facility operates on a fee-for-service business model providing investigators with customized iPS derivation and genome editing services.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Harvard Stem Cell Institute operates as a University-wide research initiative that conducts stem cell and regenerative biology research, provides shared core facilities (iPS derivation, gene editing, bioinformatics), funds early-stage research through seed and capstone grants, supports faculty startup formation, and runs training programs including internships and fellowships. Its primary mission is to translate stem cell discoveries into clinical treatments for diseases including diabetes, cancer, cardiovascular disease, and neurodegenerative conditions.

Product overview

Harvard Stem Cell Institute (HSCI) is a university-wide research initiative that functions as a collaborative platform rather than a commercial product company. The organization operates multiple interconnected research programs including disease-specific programs (Blood, Cancer, Cardiovascular, Diabetes, Kidney, Nervous System Diseases, Musculoskeletal, Skin), early-stage research funding mechanisms (Seed Grants, Capstone Grants, Barry Family Innovation Award), training programs (HIP Internship, MD/PhD Fellowship), and shared core facilities (iPS Core, Center for Stem Cell Bioinformatics, Center for Human Cell Therapy). These components work together to advance stem cell biology and translate discoveries into clinical applications for patients.

Differentiator

Problem solved

Functional benefit

Products and services

• HSCI iPS Core Facility A fee-for-service facility providing customized induced pluripotent stem (iPS) cell derivation and genome editing based on cutting-edge stem cell technologies to accelerate research in the stem cell field. Used by investigators across Harvard and partner institutions.
• HSCI Center for Stem Cell Bioinformatics (CSCB) A center providing training, consulting services, and the Stem Cell Commons collaborative data repository and analysis platform for managing high-throughput sequencing data in stem cell research.
• Center for Human Cell Therapy (CHCT)/TransLab A scientific and technical platform at Boston Children's Hospital dedicated to supporting clinical research and bench-to-bedside development of cellular therapies, providing services including cellular assays, immunophenotyping, RNA/DNA molecular assays, and FDA-compliant cell-based therapy process development.
• HSCI Internship Program (HIP) A 9-week summer research internship program providing undergraduate students with focused, hands-on research experience in cutting-edge stem cell science laboratories, including a stem cell seminar series and career pathways presentation. Housing and meal plans provided at no cost to selected interns.
• MD/PhD Training Fellowship A medical scientist training fellowship awarded to Harvard Medical School students demonstrating strong interest in stem cell research, supporting their development as physician-scientists.
• Capstone Grants 3-5 year RO1-level grants of approximately $250,000 per investigator per year for capstone projects incorporating evolving technologies to resolve issues in regenerative biology with clear line of sight to human application.
• Seed Grants Early-stage funding of $50,000 per year for up to two years for innovative projects in stem cell and regenerative biology that support bold thinking and launch scientific careers.
• Barry Family HSCI Innovation Award Annual $250,000 award for early career investigators to explore basic biology and translational potential of stem cell-based science with potential to transform the field.
• Blood Diseases Program Disease-specific research program investigating how blood stem cells manage self-renewal, with implications for leukemia, lymphoma, and regenerative medicine.
• Cancer Program Disease-specific research program working to develop therapies that can eradicate cancer cells without harming healthy tissues by understanding how normal stem cells become cancer cells.
• Cardiovascular Disease Program Disease-specific research program aimed at generating new human heart cells to replace damaged heart tissue, developing approaches to harness regeneration for therapy.
• Diabetes Program Disease-specific research program focused on curing diabetes by creating insulin-producing beta cells and protecting them from immune system attack for transplantation.
• Kidney Disease Program Disease-specific research program dedicated to finding new treatments for patients with kidney disease, focusing on nephron biology and regeneration.
• Nervous System Diseases Program Disease-specific research program investigating neurodegenerative and traumatic diseases of the brain and spinal cord, covering ALS, Alzheimer's, eye diseases, hearing loss, Multiple Sclerosis, and Parkinson's.
• Musculoskeletal Program Disease-specific research program applying stem cell and developmental biology discoveries to develop innovative solutions for musculoskeletal injury and disease using regenerative medicine approaches.
• Skin Program Disease-specific research program using stem cells to regenerate tissue without scarring, exploring fundamental roles of skin stem cells in regenerative wound healing, cancers, and skin aging.
• Stem Cells as Tools Research Platform Research platform using stem cells to study human disease in dishes at multiple levels: individual cells, multiple cell types, tissues (organoids), and bioengineered tissues, combined with gene editing capabilities.
• Harvard Fibrosis Network Cross-disciplinary network partnering with pharmaceutical companies (Bristol-Myers Squibb, Boehringer Ingelheim) to study fibrosis across kidney, lung, heart, liver, and other organs.

Quantifiable outcome

• Vertex Pharmaceuticals' VX-880 (based on Melton Lab/HSCI research) achieved promising early results as an investigational stem cell-derived islet cell replacement therapy for Type 1 diabetes.
• +3 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

23 partnerships are on record, tiered core and minor.

• Garuda TherapeuticscoreStrategic or Co-development Partner · 1 January 2021Founded by former Principal Faculty member Dhvanit Shah in 2021, Garuda Therapeutics developed a platform for generating off-the-shelf, self-renewing blood stem cells. HSCI Co-Director David Scadden is a co-founder and Scientific Advisory Board member.
• Sana BiotechnologycoreStrategic or Co-development Partner · 1 January 2019Sana Biotechnology, co-founded by HSCI Principal Faculty member Chad Cowan in 2019, is focused on creating and delivering engineered cells as medicine for patients, representing HSCI technology moving into commercial development.
• Affinia TherapeuticscoreStrategic or Co-development Partner · 1 January 2019Co-founded by HSCI Affiliate Faculty member Luk Vandenberghe in 2019, Affinia Therapeutics develops a platform for rationally designed AAV vectors and gene therapies for muscle and CNS diseases.
• AkouoscoreStrategic or Co-development Partner · 1 January 2017HSCI Affiliate Faculty member Luk Vandenberghe co-founded Akouos in 2017, a biotechnology company developing gene therapies for hearing loss.
• Alivio TherapeuticsminorStrategic or Co-development Partner · 1 January 2016HSCI Principal Faculty member Jeffrey Karp is a co-founder and Scientific Advisory Board member of Alivio Therapeutics, developing novel drug delivery technology for inflammatory disease treatment.
• Bristol-Myers SquibbcoreStrategic or Co-development PartnerBristol-Myers Squibb is a partner in the Harvard Fibrosis Network, an HSCI-led initiative that looks for commonalities across fibrotic diseases, sharing expertise in kidney, lung, heart, liver, and other organ fibrosis. The collaboration brings academic, clinical, and pharmaceutical research practice together to advance fibrosis treatments.
• Boehringer IngelheimcoreStrategic or Co-development PartnerBoehringer Ingelheim participates in the Harvard Fibrosis Network, collaborating with HSCI scientists on studies of fibrosis of the kidney, lung, heart, liver, and other organs, combining academic and pharmaceutical research approaches.
• Frequency TherapeuticscoreStrategic or Co-development PartnerHSCI scientists are collaborating with Frequency Therapeutics and the U.S. Army Institute of Surgical Research using small-molecule drugs to address different muscle conditions. HSCI Principal Faculty member Jeffrey Karp is a co-founder of Frequency Therapeutics.
• U.S. Army Institute of Surgical ResearchminorStrategic or Co-development PartnerA three-way collaboration between the U.S. Army Institute of Surgical Research, Harvard University, and Frequency Therapeutics, using small-molecule drugs to address different muscle conditions, with HSCI scientists providing stem cell research expertise.
• Vertex PharmaceuticalscoreStrategic or Co-development PartnerVertex Pharmaceuticals has developed VX-880, an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for Type 1 diabetes, utilizing research from the Melton Lab at HSCI. This represents a major translation of HSCI discoveries into clinical application.
• Boston Autologous Islet Replacement Program (BAIRT)coreStrategic or Co-development PartnerBAIRT is a unique collaboration involving HSCI, Brigham and Women's Hospital, the Joslin Diabetes Center, and the Dana-Farber Cancer Institute, working together to generate clinical-grade, pluripotent stem cells suitable for use in patients to advance beta cell replacement therapy for diabetes.
• JDRF New England Center of ExcellencecoreStrategic or Co-development PartnerHSCI is an integral member of the JDRF New England Center of Excellence, a cross-institutional collaboration with Joslin Diabetes Center, UMass Chan Medical School, Dana-Farber Cancer Institute, and the Jackson Laboratory, working toward engineering beta cells to enable transplantation without immunosuppression.
• CRISPR TherapeuticscoreStrategic or Co-development PartnerHSCI Principal Faculty member Chad Cowan is a scientific co-founder of CRISPR Therapeutics, a biopharmaceutical company created to translate CRISPR-Cas9 genome-editing technology into transformative medicines.
• Moderna TherapeuticscoreStrategic or Co-development PartnerHSCI Principal Faculty member Derrick Rossi translated a discovery from his laboratory into mRNA-based therapeutics, co-founding Moderna Therapeutics, which uses messenger RNA to produce human proteins inside patient cells.
• Semma Therapeutics (acquired by Vertex 2019)coreStrategic or Co-development PartnerSemma Therapeutics was founded by HSCI Co-Director Douglas Melton to develop transformative therapies for patients who depend on insulin injections, leveraging breakthroughs from his laboratory. Semma was acquired by Vertex Pharmaceuticals in 2019.
• Magenta TherapeuticscoreStrategic or Co-development PartnerHSCI Co-Director David Scadden and Principal Faculty member Derrick Rossi are scientific co-founders of Magenta Therapeutics, focused on improving the patient experience in transplant medicine and making bone marrow transplantation accessible to more patients.
• Fate TherapeuticscoreStrategic or Co-development PartnerHSCI Co-Director David Scadden and Executive Committee Chair Leonard Zon are co-founders of Fate Therapeutics, focused on adult stem cell modulators for rare, life-threatening disorders including hematologic malignancies and muscular dystrophies.
• EleviancoreStrategic or Co-development PartnerCo-founded by HSCI Principal Faculty members Richard Lee, Lee Rubin, and Amy Wagers, Elevian is developing regenerative medicines targeting processes that are the root causes of aging.
• Goldfinch BiominorStrategic or Co-development PartnerHSCI Executive Committee member Joseph Bonventre is a scientific co-founder of Goldfinch Bio, focused on discovering and developing precision therapies for patients with kidney disease.
• QurAlisminorStrategic or Co-development PartnerFounded by HSCI Faculty Kevin Eggan, Kasper Roet, and Clifford Woolf, QurAlis is focused on discovering and developing new therapies for ALS, the most common form of motor neuron disease.
• Keros TherapeuticsminorStrategic or Co-development PartnerKeros is a clinical-stage biopharmaceutical company focused on treatments for rare blood and musculoskeletal disorders, with HSCI Affiliate Faculty member Paul Yu as scientific founder and HSCI Executive Committee member Vicki Rosen on the Scientific Advisory Board.
• iPierian (Acquired by Bristol-Myers Squibb 2014)coreStrategic or Co-development PartnerHSCI Co-Director Douglas Melton, along with Principal Faculty members George Daley and Lee Rubin, co-founded iPierian in 2007 to develop therapies for Alzheimer's and neurodegenerative diseases. Acquired by Bristol-Myers Squibb in 2014.
• IVIVA MedicalminorStrategic or Co-development PartnerHSCI Principal Faculty member Harald Ott is founder and Chairman of the Board of IVIVA Medical, developing tissue-engineered treatments for end-stage renal disease.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Stanford Institute for Stem Cell Biology and Regenerative Medicine: Stanford's flagship stem cell research institute brings together faculty across Stanford schools and hospitals to advance regenerative medicine. It is the closest direct peer to HSCI in terms of scope, prestige, and cross-institutional model.
• Whitehead Institute for Biomedical Research: The Whitehead Institute is a leading non-profit biomedical research institute affiliated with MIT that conducts research in regenerative biology, stem cells, and disease mechanisms. It is a comparable elite-tier research organization focused on fundamental biology with translational potential.
• Buck Institute for Research on Aging: The Buck Institute is California's first biomedical research institute focused on aging and age-related diseases, with significant stem cell and regenerative biology research. It shares HSCI's focus on aging-related disease research and translational stem cell science.
• Allen Institute for Cell Science: The Allen Institute for Cell Science is a Seattle-based research institute focused on understanding cell behavior and fate using stem cell-derived models, including organoids and gene editing. It shares HSCI's emphasis on stem cell-derived platforms and tools for disease research.
• Gladstone Institutes: Gladstone Institutes is a San Francisco-based independent biomedical research organization affiliated with UCSF that focuses on regenerative medicine, stem cell biology, and disease-focused research. It has a similar disease-program structure and translational orientation to HSCI.
• Cincinnati Children's Center for Stem Cell and Organoid Medicine: This center at Cincinnati Children's Hospital is a leading pediatric stem cell research hub focused on organoid biology and regenerative medicine. It shares HSCI's emphasis on organoid technology and disease modeling.
• New York Stem Cell Foundation (NYSCF): NYSCF is a leading non-profit research organization focused on stem cell research and translational applications. It operates a research institute and works across multiple disease areas similar to HSCI, though without the embedded university network model.

Broad incumbents

• Scripps Research Institute: Scripps Research is a large non-profit biomedical research organization conducting wide-ranging research including regenerative medicine and stem cell biology. It is a broader biomedical research institution with overlapping stem cell science programs.
• Broad Institute of MIT and Harvard: The Broad Institute is a major biomedical research institution affiliated with both MIT and Harvard that conducts large-scale genomic and disease research. While broader in scope than HSCI, it shares faculty with Harvard and overlapping stem cell and regenerative biology research programs.

Regional players

• Wellcome Sanger Institute: The Wellcome Sanger Institute is a leading UK-based genomic and cellular research institute with significant stem cell biology and organoid research programs (e.g., Human Cell Atlas). It is comparable to HSCI in terms of scientific scope but operates in a different geography.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/harvardstemcell
• Facebookfacebook.com/HarvardStemCell
• LinkedInlinkedin.com/company/harvard-stem-cell-institute

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Harvard Stem Cell Institute